I don't think pricing will be an issue at all. Hard to put a...

I don't think pricing will be an issue at all. Hard to put a price on pain. The only reason why the price guide has been set this low in comparison to other drugs is because the size of the addressable market is so big. Biotechs usually figure out how much profit they wanna make from a drug and work backwards by dividing by the market size. Many orphan drugs have a much higher price tag. Eg. Orkambi for cystic fibrosis only has 30,000 patients in the US, so they sell it for $300,000 per patient per year and people still buy it. The company is called Vertex on the Nasdaq. Have a look at their recent revenues and profits.

It's really sad actually because we may one day have a scenario with PPS where OA patients are paying $3,000 a year while those poor MPS patients could be paying $50,000-100,000 a year for virtually exact same treatment. Is it fair? No, but doctors can not and will not breach the rules and lose their careers over empathy/sympathy. It's just how the pharmaceutical industry works. Sad but true.